Adequacy of Glycemic Control in Hemodialysis Patients With Diabetes
Adequacy of Glycemic Control in Hemodialysis Patients With Diabetes Daniel J. Tascona , MD , A. Ross Morton , MD , Edwin B. Toffelmire , MD , David C. Holland , MD and Eduard A. Iliescu , MD From the Division of Nephrology, Department of Medicine, Queen’s University, Kingston, Ontario, Canada Addres...
Gespeichert in:
Veröffentlicht in: | Diabetes care 2006-10, Vol.29 (10), p.2247-2251 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Adequacy of Glycemic Control in Hemodialysis Patients With Diabetes
Daniel J. Tascona , MD ,
A. Ross Morton , MD ,
Edwin B. Toffelmire , MD ,
David C. Holland , MD and
Eduard A. Iliescu , MD
From the Division of Nephrology, Department of Medicine, Queen’s University, Kingston, Ontario, Canada
Address correspondence and reprint requests to Eduard A. Iliescu, Queen’s University, 2058 Etherington Hall, Kingston, Ontario,
Canada, K7L 3N6. E-mail: eai1{at}post.queensu.ca
Abstract
OBJECTIVE —We sought to measure the prevalence of inadequate glycemic control in prevalent hemodialysis patients with diabetes and to
examine independent predictors of inadequate glycemic control in these patients.
RESEARCH DESIGN AND METHODS —This is a cross-sectional study of prevalent hemodialysis patients with diabetes in southeastern Ontario ( n = 100). Data were collected by chart review and interview. The outcome variable was inadequate glycemic control defined as
HbA 1c (A1C) >0.07. Other measured variables were diabetes type, diabetes duration, diabetes physician, blood glucose monitoring,
diabetes medications, BMI, time on dialysis, and other demographic, clinical, and laboratory variables.
RESULTS —Fifty-four patients had A1C >0.07. In bivariate analysis, these patients had a longer diabetes duration (23.6 vs.14.7 years,
P < 0.001), higher proportion with insulin use (81.5 vs. 58.7%, P = 0.012), higher proportion with microvascular complications (66.7 vs. 43.5%, P = 0.017), and lower erythropoietin (EPO) dose (7.0 vs. 11.9 × 10 3 units/week, P < 0.01) than patients with adequate glycemic control. There was no difference between the two groups in terms of macrovascular
complications (59.3 vs. 65.2%, P = 0.54). In multiple logistic regression controlling for age and diabetes type, the diabetes duration (odds ratio 1.09 [95%
CI 1.04–1.15], P < 0.001), EPO dose (0.90 [0.85–0.97], P < 0.01), and blood glucose monitoring (10.06 [1.03–98.74], P = 0.05) were the only significant independent predictors of A1C >0.07.
CONCLUSIONS —A high proportion of hemodialysis patients with diabetes had inadequate glycemic control, particularly those with longstanding
disease. Patients with inadequate glycemic control had a significantly higher burden of microvascular complications.
CKD, chronic kidney disease
DCCT, Diabetes Control and Complications Trial
EPO, erythropoietin
ESKD, end-stage kidney disease
KGH, Kingston General Hospital
UKPDS, U.K. Prospective Diabetes Study
Footnotes
A table elsew |
---|---|
ISSN: | 0149-5992 1935-5548 |
DOI: | 10.2337/dc06-0845 |